INmune Bio Future Growth
Future criteria checks 2/6
INmune Bio is forecast to grow earnings and revenue by 22% and 80.4% per annum respectively while EPS is expected to grow by 33.8% per annum.
Key information
22.0%
Earnings growth rate
33.8%
EPS growth rate
| Biotechs earnings growth | 28.3% |
| Revenue growth rate | 80.4% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 11 Nov 2024 |
Recent future growth updates
Recent updates
Is INmune Bio (NASDAQ:INMB) Using Debt In A Risky Way?
Nov 03
INmune Bio: NK Cell Therapy INKmune For mCRPC Is Another Shot On Goal
Sep 30It's Unlikely That Shareholders Will Increase INmune Bio, Inc.'s (NASDAQ:INMB) Compensation By Much This Year
Jul 12Is INmune Bio (NASDAQ:INMB) Using Debt Sensibly?
Jan 19Is INmune Bio (NASDAQ:INMB) Using Debt In A Risky Way?
Sep 04Is INmune Bio (NASDAQ:INMB) Using Too Much Debt?
May 12Here's Why INmune Bio (NASDAQ:INMB) Can Manage Its Debt Despite Losing Money
Jan 16Here's Why INmune Bio (NASDAQ:INMB) Can Manage Its Debt Despite Losing Money
Jul 11INmune Bio: Possibly The Once In A Lifetime Dip
May 25INmune Bio: Speculative Biotech With 2 Solid Potential Approaches To Treating AD And Solid Tumors
Apr 05Is INmune Bio (NASDAQ:INMB) A Risky Investment?
Mar 25Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -57 | -57 | -43 | 4 |
| 12/31/2025 | N/A | -49 | -45 | -36 | 4 |
| 12/31/2024 | 0 | -45 | -12 | -34 | 6 |
| 9/30/2024 | 0 | -41 | -26 | -26 | N/A |
| 6/30/2024 | 0 | -38 | -23 | -23 | N/A |
| 3/31/2024 | 0 | -34 | -18 | -18 | N/A |
| 12/31/2023 | 0 | -30 | -12 | -12 | N/A |
| 9/30/2023 | 0 | -27 | -14 | -14 | N/A |
| 6/30/2023 | 0 | -27 | -13 | -13 | N/A |
| 3/31/2023 | 0 | -27 | -15 | -15 | N/A |
| 12/31/2022 | 0 | -27 | -23 | -23 | N/A |
| 9/30/2022 | 0 | -31 | -27 | -27 | N/A |
| 6/30/2022 | 0 | -33 | -31 | -31 | N/A |
| 3/31/2022 | 0 | -33 | -32 | -32 | N/A |
| 12/31/2021 | 0 | -30 | -29 | -29 | N/A |
| 9/30/2021 | 0 | -24 | -21 | -21 | N/A |
| 6/30/2021 | 0 | -19 | -17 | -17 | N/A |
| 3/31/2021 | 0 | -15 | -13 | -13 | N/A |
| 12/31/2020 | 0 | -12 | -9 | -9 | N/A |
| 9/30/2020 | N/A | -11 | -7 | -7 | N/A |
| 6/30/2020 | N/A | -10 | -5 | -5 | N/A |
| 3/31/2020 | N/A | -8 | -5 | -5 | N/A |
| 12/31/2019 | N/A | -8 | -5 | -5 | N/A |
| 9/30/2019 | N/A | -7 | -5 | -5 | N/A |
| 6/30/2019 | N/A | -6 | -4 | -4 | N/A |
| 3/31/2019 | N/A | -11 | -3 | -3 | N/A |
| 12/31/2018 | N/A | -12 | -2 | -2 | N/A |
| 9/30/2018 | N/A | -11 | -2 | -2 | N/A |
| 6/30/2018 | N/A | -10 | N/A | -2 | N/A |
| 3/31/2018 | N/A | -4 | N/A | -1 | N/A |
| 12/31/2017 | N/A | -1 | N/A | -1 | N/A |
| 9/30/2017 | N/A | -1 | N/A | -1 | N/A |
| 12/31/2016 | N/A | 0 | N/A | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: INMB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: INMB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: INMB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: INMB's revenue (80.4% per year) is forecast to grow faster than the US market (9% per year).
High Growth Revenue: INMB's revenue (80.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if INMB's Return on Equity is forecast to be high in 3 years time